雷尼酸锶治疗骨质疏松症的研究进展  

The advancement of strontium ranelate treatment in osteoporosis research

作　　者：陈群[1] 王治伦[1] 刘忠厚[1] 

机构地区：[1]西安交通大学医学院地方病研究所,西安710061

出　　处：《中国骨质疏松杂志》2009年第11期844-848,共5页Chinese Journal of Osteoporosis

基　　金：国家自然科学基金重点项目(30630058);面上项目(30671820);西安市科学发展基金项目(GG06176)

摘　　要：目的对雷尼酸锶在骨质疏松症中的临床应用、作用机制进行综述和评价。方法从人群试验、动物试验、细胞培养和不良反应等方面进行综述。结果雷尼酸锶具有抗骨吸收和增进骨形成双重作用,其作用可能通过CaSR和增加血清IGF-1、降低高半胱氨酸。结论雷尼酸锶作为一种新型抗骨质疏松药物,对骨质疏松症具有良好的疗效,代表了骨质疏松症治疗的一个重要发展方向,但应注意其不良反应。Objective To evaluate the roles of strontium ranelate for clinical application and mechanism in patients with osteoporosis. Methods This article reviewed the advancement of strontium ranelate, which summarized from crowd testing, animal testing, cell culture and adverse reactions. Results Strontium ranelate can promote bone formation and decrease bone resorption, its role may be through the CaSR and increase serum IGF-1, to reduce homocysteine expression. Conclusion Strontium ranelate is a new anti-osteoporosis drug for osteoporosis. It has a good curative effect, represents the treatment direction of osteoporosis, but we should pay attention to its adverse reactions.

关 键 词：骨质疏松 CASR IGF-1 高半胱氨酸 

分 类 号：R446.1[医药卫生—诊断学] R683.4[医药卫生—临床医学]